Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.

ABSTRACT:

Background

The Phase III PROfound study (NCT02987543) evaluated olaparib versus abiraterone or enzalutamide (control; randomized 2:1 to olaparib or control) in men with homologous recombination repair gene alterations and metastatic castration-resistant prostate cancer whose disease progressed on prior next-generation hormonal agent.

Methods

We present efficacy and safety data from an exploratory post hoc analysis of olaparib in the PROfound Asian subset. Analyses were not planned, alpha controlled or powered. Of 101 Asian patients enrolled in Japan (n=57), South Korea (n=29) and Taiwan (n=15), 66 and 35 patients received olaparib and control, respectively.

Results

Radiographic progression-free survival (rPFS) and overall survival (OS) favored olaparib versus control

SUBMITTER: Matsubara N 

PROVIDER: S-EPMC9071396 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature